Zura Bio (NasdaqCM:ZURA) 2026 Conference Transcript

Summary of Zura Bio Conference Call Company Overview - Company: Zura Bio (NasdaqCM: ZURA) - CEO: Sandeep Kulkarni, co-founder, recently returned to the CEO role after Tourmaline Bio acquisition - Founded: 2022 - Pipeline: Three programs, with a focus on tibulizumab as the lead program [5][6][7] Key Programs and Developments - Tibulizumab: A bispecific antibody targeting IL-17 and BAFF, with potential first-in-class status - Indications: Focused on hidradenitis suppurativa (HS) and systemic sclerosis (SSc) - Phase 2 Trials: Two important readouts expected in 2026 and 2027 [6][10][12] Hidradenitis Suppurativa (HS) - Mechanism: Combines IL-17A blockade with BAFF inhibition, targeting multiple pathways to improve efficacy - Clinical Data: Previous studies showed high target engagement (98% for IL-17 and BAFF) [15] - Trial Design: TibuSHIELD study with 225 patients, randomized to two active drug arms and placebo, primary endpoint at week 16 [29][30] - Expected Outcomes: Aiming for a HiSCR75 delta of 20%-25% compared to placebo, reflecting clinically meaningful effects [30][42] Systemic Sclerosis (SSc) - Opportunity: No approved treatments for totality of SSc, presenting a significant market opportunity - Trial Design: TibuSURE study with 80 patients, focusing on modified Rodnan skin score and CT scans for lung function [60][62] - Regulatory Flexibility: Agency recognizes challenges in SSc, showing willingness for new treatment options [62] Market Context and Competitive Landscape - Unmet Need: HS affects approximately 8% of the population, with current treatment options being suboptimal [42] - Competitive Edge: Zura Bio's tibulizumab is positioned as a first-in-class drug targeting two different pathways, potentially offering a unique treatment profile [43][44] Additional Insights - Placebo Response Management: Over-enrollment in trials to mitigate placebo effects, careful site selection, and training for accurate measurement of clinical endpoints [38][39] - Future Directions: Data from phase 2 trials will inform phase 3 trial design, with a focus on refining treatment strategies based on patient responses [45][62] Conclusion Zura Bio is strategically positioned in the biotech space with its innovative approach to treating complex autoimmune disorders through bispecific antibodies. The upcoming phase 2 trial results for tibulizumab in HS and SSc will be critical in validating its therapeutic potential and shaping future development plans.